Cencora
COR
$338.48
-0.57%
Cencora, Inc. is one of the three dominant U.S. pharmaceutical wholesalers, sourcing and distributing branded, generic, and specialty drugs to retail chains, independent pharmacies, hospital networks, and providers, while also operating commercialization services for manufacturers, global specialty logistics through World Courier, and animal health distribution via MWI. Alongside McKesson and Cardinal Health, it controls more than 90% of the U.S. drug wholesale market, giving it an oligopolistic moat built on scale, distribution density, and manufacturer relationships rather than pricing power, since gross margins run in the low single digits. The current investor narrative centers on specialty-pharma mix shift and international expansion (Alliance Healthcare in Europe) as the engines of durable, higher-quality earnings growth, reinforced by management's September 2026 raise of FY2026 EPS guidance tied to strengthening specialty businesses. Debate now hinges on whether that specialty momentum and disciplined capital returns can offset razor-thin distribution economics, drug-pricing policy risk, and the working-capital volatility inherent to the wholesaling model.…
COR
Cencora
$338.48
Related headlines
Investment Opinion: Should I buy COR Today?
Rating: Buy (moderate conviction). The thesis is that Cencora's specialty-driven margin expansion — gross margin up from 3.27% in Q1 2026 to 4.26% in Q3 2026 — is converting a low-growth distributor into a steadier earnings compounder, and at a forward PE of 17.26x against $28.28 consensus EPS the market is not paying for that improvement. The analyst consensus of 'buy' with a mean rating of 1.79 and an average target of $370.17 implies about 8.6% upside, with a high target of $430 (about 26% above current) and a low of $330 (about 3.2% below).
Supporting evidence: revenue grew 5.07% YoY to $84.75 billion in Q3 2026 with trailing four-quarter revenue of roughly $332.7 billion; trailing free cash flow of $4.06 billion gives a ~6.7% FCF yield that covers the 0.72% dividend and the 7.13x debt load; Q3 2026 operating cash flow of $2.65 billion funded $1.0 billion of buybacks and $116.6 million of dividends; and the forward PE of 17.26x sits in the lower half of the recent 17-29x range. The main caveats are that EV/EBITDA of 17.86x and a PEG of 7.05 show the stock is not cheap on every metric, and no explicit industry-average multiples were provided, so peer benchmarking is qualitative rather than quantitative.
Key risks that could invalidate the thesis: gross margin reverting toward 3.2%, a working-capital swing like Q1 2026's -$3.40 billion pressuring the levered balance sheet, and drug-pricing policy or generic deflation compressing spread economics. The rating would upgrade to a stronger Buy if gross margin holds above 4.0% for another quarter and the stock breaks above the $377.54 high, and would downgrade to Hold if gross margin falls below 3.5% or revenue growth decelerates below 3%. Verdict: fairly valued to modestly undervalued on forward earnings, but not a bargain on EV/EBITDA — the case rests on margin durability rather than multiple expansion.
Sign up to view all
COR 12-Month Price Forecast
The forward view is constructive but not aggressive: a 17.26x forward PE on $28.28 consensus EPS prices in modest execution, and the gross margin trajectory from 3.27% to 4.26% across 2026 is the evidence that the specialty mix shift is real. Free cash flow of $4.06 billion and a 6.7% yield provide a valuation floor that is unusual for a name with a 0.581 beta and a 90%+ share oligopoly. The main constraint on conviction is earnings quality — one-off other-income and other-expense lines have swung quarterly results from a -$339.7 million loss to a $1.64 billion profit — which makes the forward estimate the only reliable anchor. I would upgrade to high confidence if gross margin holds above 4.0% for another quarter and the stock clears $377.54, and downgrade to neutral if gross margin slips below 3.5% or the $28.28 EPS estimate is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $369.08 and implied upside of +9.0% versus the current price.
Average Target
$369.08
0 analysts
Implied Upside
+9.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$330 - $400
Analyst target range
Twelve analysts cover Cencora with a consensus recommendation of "buy" and a mean rating of 1.79 on a scale where 1 is a strong buy, and the average target price of $370.17 implies roughly +8.6% upside from the current $340.92. The distribution skews bullish: recent actions include Overweight reiterations from Wells Fargo, JP Morgan, and Morgan Stanley (August 2026), Outperform from Evercore ISI, Buy from UBS, and Overweight from Barclays, with only RBC Capital at Sector Perform and B of A Securities at Neutral providing the cautious counterweight. The consensus is therefore constructive but not euphoric, and the modest implied upside reflects a stock that has already rallied 13.5% in three weeks and is approaching the average target. The target range of $330 to $430 is wide — the high target is about 26% above the current price and 16% above the average, while the low target of $330 sits roughly 3.2% below the current price. The $430 high case likely assumes accelerating specialty and international growth, multiple expansion toward the upper end of the historical PE band, and successful execution on the raised FY2026 EPS guidance, while the $330 low case prices in margin compression from generic deflation, drug-pricing policy pressure, or working-capital strain. The spread of roughly 30% between low and high signals meaningful uncertainty about the durability of the specialty-driven margin story, though the absence of any recent downgrades and the clustering of reiterations after the August earnings report suggest analysts are holding conviction rather than turning cautious; the consensus EPS estimate of $28.28 and revenue estimate of $403.4 billion provide the fundamental anchor for those targets.
Bulls vs Bears: COR Investment Factors
The bull case currently has the stronger evidence: a confirmed guidance raise, gross margin expansion from 3.27% to 4.26% across 2026, a 6.7% FCF yield, and a forward PE of 17.26x that is undemanding relative to the recent 17-29x band. The bear case rests on structural fragility rather than deterioration — 3.16% gross margins, 7.13x debt-to-equity, and earnings heavily distorted by one-off other-income and other-expense lines. The single most important tension is whether the specialty-mix margin expansion is durable: if gross margin holds near 4.26%, the $28.28 consensus EPS is credible and the stock is cheap; if it reverts toward 3.2%, the forward earnings base and the entire valuation collapse. Near-term technicals reinforce the bull side, with the stock up 13.5% in under three weeks from $300.25 to $340.92, but that also raises mean-reversion risk given a beta of 0.581.
Bullish
- Specialty-driven guidance raise: Management raised FY2026 EPS guidance in September 2026 explicitly tied to strengthening specialty businesses, and the consensus EPS estimate of $28.28 versus trailing reported figures confirms the earnings step-up is real rather than narrative. Q3 2026 gross margin of 4.26% versus 3.27% in Q1 2026 shows the mix shift is already flowing through the P&L.
- Forward PE of 17.3x is undemanding: The trailing PE of 38.97x is distorted by the Q4 2025 loss, but the forward PE of 17.26x against a $28.28 consensus EPS is a reasonable multiple for a business with an oligopoly position. The forward multiple sits in the lower half of the recent 17-29x band, leaving room for expansion if specialty growth delivers.
- Strong free cash flow and capital returns: Trailing free cash flow of $4.06 billion against a ~$60.6 billion market cap implies a roughly 6.7% FCF yield, which comfortably covers the 0.72% dividend yield and the 7.13x debt-to-equity leverage. In Q3 2026 alone the company generated $2.65 billion of operating cash flow against just $226 million of capex and returned $1.0 billion via buybacks plus $116.6 million of dividends.
- Oligopoly moat with 90%+ market share: Cencora, McKesson, and Cardinal Health control over 90% of U.S. pharmaceutical wholesale, a structural barrier that protects volume and manufacturer relationships even though gross margins are only 3.16%. Scale and distribution density are the moat, and the 5.07% YoY revenue growth to $84.75 billion in Q3 2026 shows the core is compounding.
Bearish
- Razor-thin margins leave no cushion: Gross margin of 3.16% and operating margin of 1.14% mean a small pricing or mix shock wipes out a large share of profit; Q3 2026 net margin was only 0.90%. The Q4 2025 quarter demonstrated the fragility, posting a -$339.7 million net loss driven by a -$1.04 billion other-expense line even though operating income was still $854.6 million.
- Leverage and negative working capital: Debt-to-equity of 7.13x and a current ratio of 0.903 reflect a business funded by payables and borrowings, and ROE of 103% is an artifact of a thin equity base rather than superior returns (ROA is just 3.56%). Working-capital seasonality is severe: Q1 2026 operating cash flow was -$2.31 billion on a -$3.40 billion working-capital swing.
- Earnings quality distorted by one-offs: Q2 2026 net income of $1.64 billion was boosted by a $743.6 million other-income gain, while Q4 2025 and Q1 2026 were hit by large negative other-expense lines, making the trailing PE of 38.97x and PEG of 7.05 unreliable. Investors are effectively underwriting a forward number ($28.28 EPS) that has not yet been delivered on a clean trailing basis.
- Valuation cross-checks look full: EV/EBITDA of 17.86x is a premium to the headline forward PE and is the more informative metric for a low-margin distributor, while the PEG ratio of 7.05 signals the market is paying up relative to embedded growth. The PS of 0.19x and EV/Sales of 0.231x look cheap only because of the distribution model's tiny margins.
COR Technical Analysis
Cencora is in a choppy but recovering uptrend: the stock is up 6.74% over the past year and sits at $340.92, which is roughly 70.6% of its 52-week range of $244.82 to $377.54, having recovered decisively from the May 2026 air pocket when shares gapped from about $305 to $252.74 in a single session. That positioning near the upper-middle of the range signals repaired momentum rather than overextension, though the stock remains about 9.7% below its 52-week high and has not yet reclaimed it. The 1-year gain of 6.74% also lags the S&P 500's 15.53%, reflected in a relative strength of -8.79 over twelve months, so the longer-term trend is better characterized as market-lagging consolidation than leadership. Short-term momentum is clearly accelerating: the stock is up 7.04% over one month and 10.72% over three months, versus SPY's 1.22% and 2.69%, producing relative strength of +5.82 and +8.03 respectively. This is a bullish divergence from the weak 1-year relative performance, suggesting the May drawdown marked a durable low and that institutional accumulation has resumed; the 6-month change of +4.08% (relative strength -3.40) confirms the recovery is recent rather than a full-year trend. The most recent leg is forceful, with the stock climbing from $300.25 on September 30 to $340.92 by October 16, a roughly 13.5% move in under three weeks, which raises near-term overbought risk even as it confirms demand. Key resistance sits at the 52-week high of $377.54, roughly 10.7% above the current price; a breakout there would signal a fresh leg higher and validate the specialty-growth thesis, while support rests at the 52-week low of $244.82, about 28.2% below, with intermediate support near the $300-305 area that held in late September. The beta of 0.581 is the critical risk-management input: Cencora is roughly 42% less volatile than the market, consistent with its defensive healthcare-distribution profile, which means position sizing can be larger for a given risk budget but also that the recent 13.5% surge is unusually large for this name and may mean-revert. The maximum drawdown of -32.56% shows the stock is not immune to sharp corrections, and the short ratio of 2.97 indicates modest short interest that is unlikely to fuel a squeeze but also signals no aggressive bearish conviction.
Beta
0.58
0.58x market volatility
Max Drawdown
-32.6%
Largest decline past year
52-Week Range
$245-$378
Price range past year
Annual Return
+2.3%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | +7.6% | -1.2% |
| 3m | +9.2% | +3.4% |
| 6m | +9.8% | +7.0% |
| 1y | +2.3% | +14.4% |
| ytd | -0.1% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Revenue is growing steadily rather than spectacularly: the most recent quarter (ended June 30, 2026) posted $84.75 billion, up 5.07% year over year from $80.66 billion, and the trailing four quarters total roughly $332.7 billion. The multi-quarter trend shows sequential stability with a modest acceleration in the June quarter (5.07% YoY) versus the March quarter's $78.36 billion, and segment data confirms the mix: U.S. Healthcare Solutions generated $74.86 billion, International Healthcare Solutions $7.68 billion, and Other $2.25 billion, so the domestic distribution core still drives the overwhelming majority of revenue while international and specialty are the incremental growth vectors. For a business with 3.16% gross margins, a 5% top-line growth rate translates into meaningful absolute gross-profit dollars, and the guidance raise tied to specialty businesses implies management expects this trajectory to continue. Profitability is thin but improving: Q3 2026 net income was $763.5 million on $84.75 billion of revenue, a 0.90% net margin, with gross margin of 4.26% and operating margin of 1.32%, all consistent with the low-margin distribution model. The quarterly progression is noisy but directionally positive — net income of $559.6 million in Q1 2026, $1.64 billion in Q2 (boosted by a $743.6 million other-income gain), and $763.5 million in Q3 — and the Q4 2025 loss of -$339.7 million was driven by a -$1.04 billion other-expense line rather than operating deterioration, since operating income that quarter was still $854.6 million. Gross margin has expanded from 3.27% in Q1 2026 to 4.26% in Q3 2026, a meaningful move for this industry and a key support for the earnings-guidance raise. Balance-sheet leverage is the notable risk: debt-to-equity of 7.13x reflects a heavily borrowed working-capital model, the current ratio of 0.903 is below 1.0 (typical for distributors that fund inventory with payables), and ROE of 103% is an artifact of a very thin equity base rather than exceptional returns on capital, with ROA a more modest 3.56%. Cash generation is strong, however: trailing free cash flow is $4.06 billion, Q3 operating cash flow was $2.65 billion against $226 million of capex, and the company returned capital via $1.0 billion of buybacks and $116.6 million of dividends in the quarter. The caveat is working-capital seasonality — Q1 2026 operating cash flow was -$2.31 billion on a -$3.40 billion working-capital swing — so FCF should be judged on a trailing basis; at $4.06 billion against a $60.6 billion market cap, the FCF yield is roughly 6.7%, which comfortably covers the 0.72% dividend yield and supports the debt load.
Quarterly Revenue
$84.8B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
4.3%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Because Cencora is solidly profitable (Q3 2026 net income of $763.5 million), the PE ratio is the appropriate primary metric, and the trailing PE of 38.97x versus a forward PE of 17.26x is the single most important valuation fact here. The 2.26x gap implies the market expects earnings to more than double, which is consistent with the analyst consensus EPS estimate of $28.28 versus the trailing figure distorted by the Q4 2025 loss and one-off items; on forward earnings the stock trades at a far more reasonable 17.3x. The PS ratio of 0.19x and EV/Sales of 0.231x look trivially cheap but are artifacts of the low-margin distribution model, while EV/EBITDA of 17.86x is the more informative cross-check and sits at a premium to the headline PE. Peer comparison is constrained because the provided valuation data contains no explicit industry-average multiples, so a precise premium/discount spread cannot be computed; however, the forward PE of 17.26x is broadly in line with what large-cap healthcare distributors typically command, and the PEG ratio of 7.05 is elevated, suggesting the market is paying up relative to the growth rate embedded in trailing figures. The premium implied by EV/EBITDA of 17.86x is best justified by Cencora's oligopoly position, specialty-mix shift, and 6.7% FCF yield rather than by raw growth. Historical context shows the stock's own PE band has been extremely wide and distorted by one-off items: 17.91x in Q3 2026, 9.31x in Q2 2026, 29.32x in Q1 2026, and a meaningless -44.65x in Q4 2025, while the PS ratio has been far more stable, moving from 0.72x in Q4 2025 to 0.64x in Q3 2026 and 0.19x on the current trailing basis. The current forward PE of 17.26x sits in the lower half of the recent 17-29x range, implying the market is not pricing in optimistic expectations and that there is room for multiple expansion if specialty growth delivers; the PB ratio of 40.17x is not analytically useful given the thin equity base.
PE
39.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the wholesaling model's thin cushion and heavy leverage. Gross margin of 3.16% and operating margin of 1.14% mean a modest change in generic deflation or specialty mix can erase a large share of profit, and Q3 2026 net margin was just 0.90%. Debt-to-equity of 7.13x with a current ratio of 0.903 shows the balance sheet is funded by payables and borrowings, and working-capital swings are violent — Q1 2026 operating cash flow was -$2.31 billion on a -$3.40 billion working-capital move. Earnings quality is also a risk: Q2 2026's $1.64 billion net income included a $743.6 million other-income gain, while Q4 2025's -$339.7 million loss came from a -$1.04 billion other-expense line, so headline figures can swing wildly around a stable operating base.
Market and competitive risks are moderate but real. The forward PE of 17.26x is reasonable, but EV/EBITDA of 17.86x and a PEG of 7.05 mean the stock is not statistically cheap on cross-checks, leaving limited multiple cushion if growth slows. The beta of 0.581 means roughly 42% less market volatility than the S&P 500, which is a defensive virtue but also implies the recent 13.5% three-week surge is unusually large for this name and prone to mean reversion. Competitive pressure comes from McKesson and Cardinal Health in a 90%+ share oligopoly where differentiation is operational rather than pricing-based, and drug-pricing policy plus generic deflation remain structural overhangs; the September 2026 news flow shows peers like Cardinal Health still extracting 8-11% pharma segment profit growth, so relative execution matters.
Worst-case scenario: specialty margin expansion reverses, gross margin falls back toward the 3.2% level seen in Q1 2026, and the $28.28 consensus EPS proves unreachable, forcing analysts toward the $330 low target or below. A simultaneous working-capital squeeze like Q1 2026's -$3.40 billion swing would pressure the 7.13x levered balance sheet and likely trigger a de-rating toward the 52-week low of $244.82, which is about 28.2% below the current $340.92. The stock's maximum drawdown of -32.56% confirms such a move is historically plausible, implying an investor could lose roughly 28-33% from current levels in an adverse scenario.
FAQ
Ranked by severity: first, margin fragility — gross margin of 3.16% and operating margin of 1.14% mean a small pricing or mix shock erases a large share of profit, and Q4 2025 showed a -$339.7 million net loss from a -$1.04 billion other-expense line. Second, balance-sheet and working-capital risk — debt-to-equity of 7.13x, a current ratio of 0.903, and Q1 2026 operating cash flow of -$2.31 billion on a -$3.40 billion working-capital swing. Third, earnings-quality risk — Q2 2026's $1.64 billion net income included a $743.6 million other-income gain, so headline numbers are volatile. Fourth, policy and competitive risk — drug-pricing legislation and generic deflation in a 90%+ share oligopoly where McKesson and Cardinal Health compete on execution, with the stock already 9.7% below its $377.54 high.
The 12-month outlook has three scenarios: a 55% base case of $355-$385, anchored on the $370.17 analyst average target and earnings near the $28.28 consensus with gross margin holding at 4.0-4.3%; a 25% bull case of $400-$430, requiring margin above 4.3% and a breakout above the $377.54 high; and a 20% bear case of $245-$330, driven by margin reversion toward 3.2% and a working-capital squeeze. The base case is most likely because it requires only that the current margin trajectory holds and revenue growth stays near 5.07%, both of which are already evidenced in Q3 2026 results. The key assumption is that specialty-mix gross margin gains are structural rather than a one-quarter phenomenon.
The valuation depends heavily on which metric you trust. The trailing PE of 38.97x looks expensive, but it is distorted by the Q4 2025 loss and one-off items, while the forward PE of 17.26x on $28.28 consensus EPS is reasonable and sits in the lower half of the recent 17-29x band. EV/EBITDA of 17.86x and a PEG of 7.05 are less forgiving and suggest the stock is not cheap on every cross-check, while the PS of 0.19x and EV/Sales of 0.231x are artifacts of the 3.16% gross margin model. The market appears to be pricing modest specialty-driven earnings growth rather than optimism, implying fair value to modest undervaluation on forward earnings, with limited multiple cushion on EV/EBITDA.
From a risk/reward perspective, COR offers roughly 8.6% upside to the $370.17 analyst average target and about 26% to the $430 high target, against downside of about 3.2% to the $330 low target and roughly 28% to the $244.82 52-week low. The forward PE of 17.26x on $28.28 consensus EPS is undemanding, and a ~6.7% free cash flow yield on $4.06 billion of trailing FCF provides a valuation cushion. The biggest downside risk is a reversal of the gross margin expansion from 3.27% to 4.26%, which would invalidate the forward earnings base. It is a reasonable buy for patient, risk-aware investors comfortable with a 0.581 beta and thin-margin distribution economics, but the recent 13.5% three-week rally argues for scaling in rather than chasing.
COR is better suited to long-term holding than short-term trading. Its beta of 0.581 means roughly 42% less volatility than the market, which limits the payoff from tactical trading, and the 0.72% dividend yield with a 28.1% payout ratio rewards patience rather than turnover. The business is a mature, 90%+ share oligopoly growing revenue at 5.07% YoY, not a high-growth story, so earnings visibility comes from specialty mix and international expansion rather than rapid top-line acceleration. However, the stock's -32.56% maximum drawdown and the May 2026 single-session gap from about $305 to $252.74 show it is not immune to sharp corrections, so a minimum holding period of 12-18 months is appropriate to ride through working-capital seasonality and let the margin story prove out.